Publications by authors named "Danea Horn"

Claim this Profile
C
Comparison of Food and Drug Administration expedited approvals and guideline updates: A case study of immune checkpoint inhibitors in colon cancer care.
Danea M Horn, Kathryn A Phillips, Kevin A Schulman

Cancer Lett· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current landscape of US Food and Drug Administration use of expedited regulatory approvals for colorectal cancer care.
Danea M Horn, Mireille Jacobson, Kathryn A Phillips

J Manag Care Spec Pharm· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incentive to treat: Physician agency and the expansion of the 340B drug pricing program.
Danea Horn

J Health Econ· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions: How can the United States harness technological innovation to transform its healthcare system to improve population health outcomes?
Robert M Califf, Danea M Horn, Kathryn A Phillips

Health Aff Sch· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review and Publication Times and Reporting Across Journals on Health Policy.
Kathryn A Phillips, Danea M Horn

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bringing value to cancer research.
Casey J Allen, Horn M Danea, Fabrice Smieliauskas, Stephen Edge, Rachel A Greenup

Front Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From prevention to treatment: Prescription medication, information, and health behaviors.
Danea Horn

Health Econ· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
Danea M Horn, Mireille Jacobson, Abby E Alpert, Mark G Duggan

JCO Oncol Pract· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey.
Casey J Allen, Rebecca A Snyder, Danea Marie Horn, Matthew F Hudson, Anne Barber

JCO Oncol Pract· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
Danea M Horn, Abby E Alpert, Mark G Duggan, Nicolas A Garcia, Mireille Jacobson

JCO Oncol Pract· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technology adoption and market allocation: The case of robotic surgery.
Danea Horn, Adam Sacarny, Annetta Zhou

J Health Econ· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incomplete program take-up during a crisis: evidence from the COVID-19 shock in one U.S. state.
Marianne Bitler, Jason Cook, Danea Horn, Nathan Seegert

Int Tax Public Financ· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Colorectal Cancer Control Program.
Marianne P Bitler, Christopher S Carpenter, Danea Horn

Health Econ· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis